This crossover trial compares individual urine albumin-creatinine ratio responses to dapagliflozin therapy, after re-exposure to dapagliflozin, and to placebo among patients with type 2 diabetes and albuminuria. Here, ALB is linked to type 2 diabetes mellitus.